Optamont (Olopatadine)

Olopatadine works by selectively blocking histamine H1 receptors on mast cells and conjunctival tissues. This inhibition prevents the release of histamine and other inflammatory mediators, stabilising mast cells and reducing vascular permeability, which together alleviate the ocular and nasal symptoms of allergic reactions.

The dosage of Optamont is determined by the prescribing clinician based on the patient’s age, condition and response to therapy. Typical regimens involve instilling one drop into each affected eye one to two times daily, but the exact schedule should follow the healthcare provider’s instructions.

Safety data for olopatadine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare professional.

To place an order, submit an enquiry on the Optamont product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Optamont (olopatadine) offers both antihistamine and mast‑cell stabilising activity, providing rapid symptom relief and longer‑lasting control. Compared with alternatives such as ketotifen or azelastine, olopatadine generally has a lower incidence of ocular irritation and a comparable efficacy profile, making it a preferred option for many clinicians treating allergic eye disease.

Optamont should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use to maintain stability and potency.

Instill the prescribed number of drops into the conjunctival sac of each eye, usually one drop per eye. Avoid touching the tip of the bottle to the eye or any other surface. Wash your hands before and after application, and follow any additional instructions provided by the prescribing clinician.

Although rare, serious adverse events can include severe allergic reactions such as anaphylaxis, corneal edema or ulceration, and life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should seek immediate medical attention if they experience symptoms such as intense eye pain, vision changes, widespread rash, or swelling of the face and throat.

Optamont should not be used by individuals with a known hypersensitivity to olopatadine or any of the excipients in the formulation. It is also contraindicated in patients with active severe ocular infection, those who have undergone recent ocular surgery without clearance, and children younger than two years unless specifically advised by a qualified eye‑care professional.